Changes in insulin utilization in China from 2020 to 2022
From 2020 to 2022, the procurement of insulin increased, which may be due to the increased attention for diabetes from the country and residents.However, the proportion of insulin among all antidiabetic medicines was essentially unchanged, while the use of some non-insulin hypoglycemic drugs increased significantly, especially the SGLT2i and GLP-1 RA. Given the economic and cultural diversity, Insulin procurement and utilization patterns varied greatly across the regions. Owning domestic enterprises potentially influences the procurement of insulin. Enhancing education to further improve the self-management of patients with diabetes is essential.
Authors
- Caijun Yang (ORCID: https://orcid.org/0000-0001-5127-7075)
- Yu Fang
- Shuchen Hu (ORCID: https://orcid.org/0000-0001-7146-6463)
- Xingyu Liu (ORCID: https://orcid.org/0009-0007-5748-3938)
- Jieqiong Zhang (ORCID: https://orcid.org/0000-0002-6721-3196)
- Jinwei Zhang (ORCID: https://orcid.org/0009-0008-6841-9090)
- Xiaoyong Liu (ORCID: https://orcid.org/0009-0007-1438-805X)
- Chen Chen (ORCID: https://orcid.org/0000-0001-5574-7564)
Institutions
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-23
- DOI
- https://doi.org/10.1111/dom.15936
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- National Natural Science Foundation of China